Clinical trial
Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study Of AG-013736 In Combination With Docetaxel Versus Docetaxel Alone In Patients With Metastatic Breast Cancer Preceded By A Phase 1 Evaluation Of The Combination
NCT00076024 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study Of AG-013736 In Combination With Docetaxel Versus Docetaxel Alone In Patients With Metastatic Breast Cancer Preceded By A Phase 1 Evaluation Of The Combination
- Lead sponsor
- Pfizer
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- February 29, 2004
- Completion date
- November 30, 2008
- Enrollment
- 174 (actual)
- Sites
- 54
Conditions
As the registry lists them; a condition with its own page is linked.